Dual-Target CAR-T Cell Therapy Shows Promise in Slowing Aggressive Brain Tumors
05/06/2025
A groundbreaking dual-target CAR-T cell therapy has shown remarkable results in slowing recurrent glioblastoma (GBM) progression. In a Phase 1 trial, 62% of patients experienced tumor regression, with some surviving over a year—a rare outcome for this aggressive brain cancer. Learn how this innovative approach could change GBM treatment.